PBLA

Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025

Retrieved on: 
Monday, April 22, 2024
MSN, Safety, Protein-bound paclitaxel, OTCQB, Prognosis, Survival, Oxaliplatin, Doctor of Philosophy, Therapy, Patient, Fluorouracil, Dicarboxylic acid, Data analysis, PBLA, Pharmaceutical industry

MINNEAPOLIS, April 22, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that the interim data analysis for its ongoing ASPIRE trial is now expected to be available as soon as Q1 2025.

Key Points: 
  • MINNEAPOLIS, April 22, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that the interim data analysis for its ongoing ASPIRE trial is now expected to be available as soon as Q1 2025.
  • As of the latest assessment, less than half of the required events for the interim analysis have occurred.
  • "The early indications from the ASPIRE trial support this belief, and we remain committed to advancing this important study and look forward to sharing the interim results in March 2025."
  • Panbela will continue to monitor the progress of the ASPIRE trial and provide updates as appropriate.

Panbela Announces Transfer to OTCQB Market

Retrieved on: 
Tuesday, April 16, 2024
OTCQB, Section, Therapy, Patient, PBLA

MINNEAPOLIS, April 16, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that its common stock has been approved for quotation on the OTCQB market.

Key Points: 
  • MINNEAPOLIS, April 16, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that its common stock has been approved for quotation on the OTCQB market.
  • OTCQB is recognized by the U.S. Securities and Exchange Commission (the “SEC”) as an established public market and provides current public information to investors who need to analyze, value, and trade securities.
  • Panbela’s board of directors also has approved the delisting of its common stock from The Nasdaq Stock Market LLC (“Nasdaq”).
  • Panbela intends to file its own Form 25 in advance of Nasdaq’s expected filing of a Form 25, primarily to expedite the transition of its common stock to the OTCQB.

Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results

Retrieved on: 
Tuesday, March 26, 2024
Research, Topotecan, PBLA, Neuroblastoma, Patient, Data monitoring committee, Acquisition, Celecoxib, Doctor of Philosophy, AACR, MSN, CPP, Pancreatic cancer, Therapy, DSMB, Poster, DFMO, Cyclophosphamide, Pharmaceutical industry

MINNEAPOLIS, March 26, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter and full year ended December 31, 2023.

Key Points: 
  • MINNEAPOLIS, March 26, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter and full year ended December 31, 2023.
  • “Looking ahead, Panbela remains unwavering in its commitment to patients and in its pursuit of maximizing value for stockholders.
  • Notes payable, plus accrued interest, on the balance sheet, the result of the acquisition of CPP, totaled approximately $5.4 million.
  • Gross proceeds from the raise, which closed on January 31, 2024, were approximately $9 million.

Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024

Retrieved on: 
Tuesday, March 12, 2024
Therapy, Patient, PBLA

MINNEAPOLIS, March 12, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on March 26, 2024, at 4:30 PM Eastern Time to discuss results for its fourth quarter and year ended December 31, 2023.

Key Points: 
  • MINNEAPOLIS, March 12, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on March 26, 2024, at 4:30 PM Eastern Time to discuss results for its fourth quarter and year ended December 31, 2023.

Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements

Retrieved on: 
Thursday, February 15, 2024
Therapy, Letter, PBLA, Patient

MINNEAPOLIS, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that, has regained compliance with applicable listing standards of The Nasdaq Stock Market (“Nasdaq”) for bid price and publicly held shares.

Key Points: 
  • MINNEAPOLIS, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that, has regained compliance with applicable listing standards of The Nasdaq Stock Market (“Nasdaq”) for bid price and publicly held shares.
  • Nasdaq has issued notice that Panbela has regained compliance for continued listing of its common stock.
  • On February 13, 2024, Panbela received a letter from Nasdaq confirming that Panbela has cured the previously identified minimum bid price and the publicly held shares requirements, under Nasdaq Listing Rules 5550(a)(2) and 5550(a)(4).
  • The Company will be presenting its plan to the Nasdaq Hearings Panel regarding equity compliance.

Panbela Announces Closing of Approximately $9.0 Million Public Offering

Retrieved on: 
Thursday, February 1, 2024
Roth Capital Partners, Therapy, Patient, Prospectus, Sale, PBLA, Suite, Form, Security (finance)

The Public Warrants have an exercise price of $2.06 per share, are exercisable upon issuance, and will expire five years following the date of issuance.

Key Points: 
  • The Public Warrants have an exercise price of $2.06 per share, are exercisable upon issuance, and will expire five years following the date of issuance.
  • The Public Warrants do not have any alternative cashless exercise or other provisions to adjust their exercise price beyond customary proportionate adjustments for recapitalizations and similar events.
  • Roth Capital Partners acted as sole placement agent of the offering.
  • Gross proceeds, before deducting placement agent fees and commissions and offering expenses, were approximately $9.0 million.

Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)

Retrieved on: 
Tuesday, January 30, 2024
AACR, Therapy, PBLA, Poster, Patient, Cancer, Online shopping

MINNEAPOLIS, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced that an abstract for SBP-101, a proprietary polyamine analogue, has been accepted for poster presentation at the American Association for Cancer Research (AACR), which will be held April 5-10, 2024.

Key Points: 
  • MINNEAPOLIS, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced that an abstract for SBP-101, a proprietary polyamine analogue, has been accepted for poster presentation at the American Association for Cancer Research (AACR), which will be held April 5-10, 2024.
  • The work reflects the Company’s on-going collaboration with Johns Hopkins University School of Medicine.
  • Details of the presentation are as follows:
    Additional meeting information can be found on the AACR website: https://www.aacr.org/meeting/aacr-annual-meeting-2024/abstracts/
    The abstract and poster will also be available on the Company's website at https://panbela.com/events-presentations/ once the information has been released by AACR.

Panbela Announces Pricing of Approximately $9.0 Million Public Offering

Retrieved on: 
Monday, January 29, 2024
Patient, Therapy, PBLA, Form S-1, Prospectus, Form, Sale, Suite, Roth Capital Partners, Common, Security (finance)

The Common Warrants do not have any alternative cashless exercise or other provisions to adjust their exercise price beyond customary proportionate adjustments for recapitalizations and similar events.

Key Points: 
  • The Common Warrants do not have any alternative cashless exercise or other provisions to adjust their exercise price beyond customary proportionate adjustments for recapitalizations and similar events.
  • The offering is expected to close on or about January 31, 2024, subject to customary closing conditions.
  • Roth Capital Partners is acting as sole placement agent of the offering.
  • Gross proceeds, before deducting placement agent fees and commissions and offering expenses, are expected to be approximately $9.0 million.

Panbela Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer, Exceeding Anticipated Timelines with Accelerated Momentum

Retrieved on: 
Thursday, January 25, 2024
Doctor of Philosophy, Patient, Data analysis, MSN, Therapy, PBLA, Pancreatic cancer, Pharmaceutical industry

ASPIRE is a global randomized, double-blind placebo-controlled clinical trial to evaluate ivospemin in combination with gemcitabine and nab-Paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma.

Key Points: 
  • ASPIRE is a global randomized, double-blind placebo-controlled clinical trial to evaluate ivospemin in combination with gemcitabine and nab-Paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma.
  • Detailed information on the trial can be located at https://clinicaltrials.gov/ct2/show/NCT05254171 .
  • “We’re thrilled to have surpassed 50% enrollment for the ASPIRE trial and to be moving faster than originally projected,” said Jennifer K. Simpson, PhD, MSN, CRNP, President & Chief Executive Officer of Panbela.
  • Panbela is committed to delivering a more effective treatment for pancreatic cancer, a deadly disease with few treatment options.

Panbela Announces Publication of Clinical Data Titled: Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial

Retrieved on: 
Thursday, January 18, 2024
DFMO, Pediatrics, Patient, Therapy, Biology, MD, PBLA, Prostate cancer, University, Celecoxib, Neuroblastoma, Risk, PD, PFS, FDA, Doctor of Philosophy, MYC, Pharmaceutical industry

According to Hogarty et al, children with relapsed refractory neuroblastoma have dismal outcomes and new therapeutic options are needed.

Key Points: 
  • According to Hogarty et al, children with relapsed refractory neuroblastoma have dismal outcomes and new therapeutic options are needed.
  • The work reflects the Company’s previous collaboration with New Advances in Neuroblastoma Therapy Consortium (NANT) (https://www.nant.org/).
  • From the Phase 1 dose range finding study of CPP-1X in heavily pretreated neuroblastoma patients, CPP-1X was well tolerated.
  • “We are excited about the publication of these Phase 1 trial results in light of the recent DFMO FDA approval for patients in maintenance therapy.